VANCOUVER, British Columbia, Dec. 13, 2017 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a tellurian bioactive phytoceutical dignitary specializing in a enlargement of curative and wellness products, is gratified to announce Be Trū Organics™ has commenced a routine of distributing product to Erewhon Natural Foods, a premier supermarket sequence in California.
“We are always looking for new ways to enhance a company’s strech and serve variegate a product offerings,” pronounced Marcos Agramont, CEO of Isodiol. “We sealed a 100% merger of Be Trū final week, and in this brief volume of time, we have already seen clever formula from this partnership. This partnership will continue to open additional income streams, and capacitate Isodiol to dig a mainstream marketplace and yield consumers with natural, high-quality, health and wellness products.”
Since a late 1960s, Erewhon has been committed to providing dishes and products that change a lives of consumers. Erewhon sets a customary for a top peculiarity mixture probable and forever works towards providing their consumers with a best dishes and products a earth can offer.
“Be Trū is really gratified to share this refurbish and we design many some-more opportunities to benefaction themselves in a entrance months,” pronounced Keith Gordon, CEO of Be Trū Organics. “As we pierce along in a partnership with Isodiol, we will start to embody their products in a distribution.”
For some-more information on Isodiol, greatfully revisit www.isodiol.com
For some-more information on Be Trū Organics™, greatfully revisit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is a marketplace personality in curative class phytochemical compounds and a attention personality in a production and enlargement of phytoceutical consumer products.
Isodiol is a colonize of many firsts for a cannabis attention including commercialization of 99%+ pure, bioactive curative class cannabinoids, micro-encapsulations, and nanotechnology for a top peculiarity consumable and accepted skin caring products.
Isodiol’s enlargement devise includes a enlargement of over-the-counter and curative drugs, expanding a phytoceutical portfolio and will aggressively continue general enlargement into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Forward-Looking Information: This news recover contains “forward-looking information” within a definition of germane bonds laws relating to statements per a Company’s business, products and destiny of a Company’s business, a product offerings and skeleton for sales and marketing. Although a Company believes that a expectations reflected in a forward-looking information are reasonable, there can be no declaration that such expectations will infer to be correct. Readers are cautioned to not place undue faith on forward-looking information. Such brazen looking statements are theme to risks and uncertainties that might means tangible results, opening and developments to differ materially from those contemplated by these statements depending on, among other things, a risks that a Company’s products and devise will change from those settled in this news recover and a Company might not be means to lift out a business skeleton as expected. Except as compulsory by law, a Company specifically disclaims any obligation, and does not intend, to refurbish any forward-looking statements or forward-looking information in this news release. Although a Company believes that a expectations reflected in a forward-looking information are reasonable, there can be no declaration that such expectations will infer to be scold and creates no anxiety to profitability formed on sales reported. The statements in this news recover are done as of a date of this release.
The CSE has not reviewed, authorized or disapproved a calm of this press release.
